EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY-NC-ND 4.0

Development and validation of a UPLC-MS/MS method for real-time neuropharmacokinetic monitoring of iboga alkaloids in rat brain

Scot McIntosh, Isabella Maldonado, Nickalus C Smith, Rama S Gadepalli, John M Rimoldi, Vaclav Havel, Dalibor Sames, Scott E Hemby

Journal of Pharmaceutical and Biomedical Analysis · 2026-11 · 280 · 117630

DOI: 10.1016/j.jpba.2026.117630 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Journal of Pharmaceutical and Biomedical Analysis, 2026-11. Verfasst von Scot McIntosh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Pharmaceutical Sciences, Fred Wilson School of Pharmacy, High Point University, High Point, NC, USA. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Brain, Ibogaine. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDA NIH HHS, National Institute of General Medical Sciences, National Institute on Drug Abuse.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Iboga alkaloids, including ibogaine, its primary metabolite noribogaine, and the naturally occurring congener ibogamine, have shown promise for the treatment of substance use and other neuropsychiatric disorders but are limited by cardiotoxic effects. Safer synthetic analogs, such as oxa-noribogaine, are under active development; however, validated analytical methods for quantifying these compounds in brain extracellular fluid are lacking. Existing approaches that rely on tissue homogenate analysis reflect total tissue drug content, encompassing intracellular, protein-bound, and vascular compartments, and cannot directly measure pharmacologically active, unbound drug at the site of receptor interaction. Here, we report the development and validation of a sensitive UPLC-MS/MS method capable of quantifying ibogaine, noribogaine, ibogamine, and oxa-noribogaine in rat brain microdialysate. Using D2-noribogaine, a custom-synthesized isotopically labeled internal standard, the method achieved lower limits of quantification of 0.78-1.56 ng/mL with a 6-minute run time. Calibration curves were linear over 0.78-75 ng/mL for ibogamine and 1.56-75 ng/mL for ibogaine, noribogaine, and oxa-noribogaine, and intra- and inter-day accuracy and precision met acceptance criteria for all analytes. Analytes were stable under freeze–thaw, long-term storage (−80°C), and autosampler conditions. The method was successfully applied to measure noribogaine levels in the nucleus accumbens following intraperitoneal administration (10 mg/kg) in rats (n=4), yielding a recovery-corrected peak unbound extracellular fluid (ECF) concentration (C max,u ) of 292 ± 68 ng/mL (~0.98 µM) at a mean T max of 50 minutes, demonstrating the method's suitability for real-time neuropharmacokinetic profiling of iboga alkaloids in brain ECF. This validated method provides an essential preclinical tool for pharmacokinetic–pharmacodynamic characterization of iboga alkaloids at their sites of therapeutic action, supporting the development of safer iboga-derived therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tandem Mass SpectrometryBrainIbogaineAnimalsRatsChromatography, High Pressure LiquidMaleMicrodialysisRats, Sprague-DawleyLiquid Chromatography-Mass SpectrometryReproducibility of ResultsAlkaloidsCalibrationLimit of Detection

Stichwörter der Autor:innen

Bioanalytical method validationBrain microdialysisIboga alkaloidsNeuropharmacokineticsUPLC-MS/MS

Substanzen

IbogainenoribogaineAlkaloids

Autor:innen und Institutionen

  • Department of Basic Pharmaceutical Sciences, Fred Wilson School of Pharmacy, High Point University, High Point, NC, USA.
  • Department of Neuroscience, High Point University, High Point, NC, USA.
  • Department of Biomolecular Sciences, School of Pharmacy, University of Mississippi, MS, USA.
  • Department of Chemistry and the Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY, USA.
  • Department of Basic Pharmaceutical Sciences, Fred Wilson School of Pharmacy, High Point University, High Point, NC, USA. Electronic address: shemby@highpoint.edu.

Förderung

  • NIDA NIH HHS
  • National Institute of General Medical Sciences
  • National Institute on Drug Abuse
  • National Institutes of Health

Zitieren

APA

McIntosh, S., Maldonado, I., Smith, N. C., Gadepalli, R. S., Rimoldi, J. M., Havel, V., Sames, D., & Hemby, S. E. (2026). Development and validation of a UPLC-MS/MS method for real-time neuropharmacokinetic monitoring of iboga alkaloids in rat brain. Journal of Pharmaceutical and Biomedical Analysis, 280, 117630. https://doi.org/10.1016/j.jpba.2026.117630

Vancouver

McIntosh S, Maldonado I, Smith NC, Gadepalli RS, Rimoldi JM, Havel V, et al. Development and validation of a UPLC-MS/MS method for real-time neuropharmacokinetic monitoring of iboga alkaloids in rat brain. Journal of Pharmaceutical and Biomedical Analysis. 2026;280:117630. doi:10.1016/j.jpba.2026.117630

BibTeX
@article{McIntosh2026,
  author = {McIntosh, Scot and Maldonado, Isabella and Smith, Nickalus C and Gadepalli, Rama S and Rimoldi, John M and Havel, Vaclav and Sames, Dalibor and Hemby, Scott E},
  title = {Development and validation of a UPLC-MS/MS method for real-time neuropharmacokinetic monitoring of iboga alkaloids in rat brain},
  journal = {Journal of Pharmaceutical and Biomedical Analysis},
  year = {2026},
  volume = {280},
  pages = {117630},
  doi = {10.1016/j.jpba.2026.117630}
}
Kostenlos starten →